Plasmodium falciparum

Plasmodium falciparum
Name	Plasmodium falciparum
Domain	Eukaryota
Kingdom	Chromista
Phylum	Apicomplexa
Class	Aconoidasida
Order	Haemospororida
Family	Plasmodiidae
Genus	Plasmodium
Species	P. falciparum
Binomial	Plasmodium falciparum
Binomial authority	(Welch, 1897)

Plasmodium falciparum is a unicellular protozoan parasite and the most lethal causative agent of malaria in humans. It is transmitted through the bite of an infected female Anopheles mosquito. The parasite's complex life cycle involves both a human host and a mosquito vector, leading to severe disease manifestations such as cerebral malaria and severe malarial anemia. Its significant morbidity and mortality have made it a primary target for global public health initiatives led by organizations like the World Health Organization.

Biology and life cycle

The life cycle begins when sporozoites are injected into the human bloodstream during a mosquito bite, traveling to the liver to infect hepatocytes. This exoerythrocytic schizogony results in merozoites that rupture into the blood, initiating the erythrocytic cycle within red blood cells. Here, the parasite progresses from ring to trophozoite to schizont stages, with some parasites differentiating into sexual gametocytes. These gametocytes are taken up by another Anopheles during a blood meal, where they undergo sporogony in the mosquito's midgut and salivary glands, completing the cycle. Key biological features include the PfEMP1 protein, encoded by the var gene family, which mediates cytoadherence to endothelial cells.

Epidemiology and distribution

Transmission is endemic in tropical and subtropical regions, with the highest burden in sub-Saharan Africa. Other significant foci include parts of Southeast Asia, the Amazon Basin, and Papua New Guinea. The primary vector is the Anopheles gambiae complex in Africa. Epidemiology is influenced by factors such as climate, rainfall, and the implementation of control programs. Major initiatives like the Roll Back Malaria Partnership and funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria aim to reduce incidence. The World Malaria Report annually details progress and challenges in these endemic countries.

Pathogenesis and clinical features

Pathogenesis is largely due to sequestration of infected erythrocytes in the microvasculature of vital organs, mediated by PfEMP1 binding to host receptors like ICAM-1. This can lead to cerebral malaria, characterized by coma and seizures, and severe malarial anemia from hemolysis and dyserythropoiesis. Other complications include acute respiratory distress syndrome, hypoglycemia, and renal failure. The classic symptom of cyclic fever correlates with the synchronous rupture of schizonts. Susceptibility is influenced by host genetics, such as the protective sickle cell trait.

Diagnosis and treatment

Definitive diagnosis relies on microscopic examination of Giemsa-stained blood smears or rapid diagnostic tests detecting parasite antigens like HRP2. Molecular methods such as PCR are used for confirmation and species identification. First-line treatment for uncomplicated cases involves artemisinin-based combination therapies, such as artemether-lumefantrine. For severe malaria, intravenous artesunate is recommended. Drug resistance, particularly to chloroquine and emerging artemisinin resistance in the Greater Mekong Subregion, poses a major therapeutic challenge, monitored by networks like the WorldWide Antimalarial Resistance Network.

Prevention and control

Prevention strategies center on vector control using insecticide-treated bed nets and indoor residual spraying with compounds like DDT or pyrethroids. Chemoprevention includes intermittent preventive treatment for pregnant women and seasonal malaria chemoprevention for children in the Sahel. Vaccine development achieved a milestone with the RTS,S/AS01 vaccine, recommended by the World Health Organization for use in endemic areas. Other approaches under investigation involve genetic modification of Anopheles populations and novel antimalarial compounds.

History and research

The parasite was first described by Alphonse Laveran in 1880 and its transmission by Anopheles proven by Ronald Ross in 1897. The species name was formalized by William H. Welch. Historical treatments included quinine and later chloroquine, discovered at the Bayer laboratories. The complete genome was sequenced in 2002 by the Plasmodium falciparum Genome Project, a consortium including the Sanger Institute and The Institute for Genomic Research. Ongoing research focuses on understanding drug resistance mechanisms, developing next-generation vaccines targeting circumsporozoite protein, and investigating novel transmission-blocking strategies.

Category:Apicomplexa Category:Human diseases and disorders Category:Parasites